TY - JOUR
T1 - Nanoparticles for colorectal cancer targeted drug delivery and mr imaging
T2 - Current situation and perspectives
AU - Dong, Zhi
AU - Cui, Min Yi
AU - Peng, Zhenpeng
AU - Li, Yin
AU - Wang, Xiaoling
AU - Fang, Zhuangnian
AU - Jiang, Mengjie
AU - Xu, Ling
AU - Luo, Yanji
AU - Li, Zi Ping
AU - Feng, Shi Ting
N1 - Publisher Copyright:
© 2016 Bentham Science Publishers.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - The application of nanoparticles (NPs) offers new prospects for the early detection and effective therapy of colorectal cancer (CRC). Various NPs have been designed and explored as diagnostic and/or therapeutic drug delivery vehicles. To achieve selective treatment and to reduce toxicity, these nanoparticles are usually endowed with targeting abilities. Passive targeting is based on the extravasation and enhanced permeability and retention effect of tumors, while active targeting always involves binding to specific ligands that are recognizable by CRC tissues, such as vascular endothelial growth factor, folate, monoclonal antibodies (mAbs), aptamers, and membrane penetrating peptides. In addition, contrast agents, such as gadolinium complexes and iron oxide particles, can be introduced into the delivery system to enable MR imaging and lesion detection. Furthermore, smart carriers have been gradually applied to the delivery system. These carriers are designed to respond to certain changes in the bio-environment and release encapsulated contents on demand, thus achieving effective drug concentrations at tumor sites. This review focuses on recent advances of NP technology for the targeted diagnosis and treatment of CRC and aims to unveil the emerging possibilities of using nanocarriers to enhance therapeutic applications.
AB - The application of nanoparticles (NPs) offers new prospects for the early detection and effective therapy of colorectal cancer (CRC). Various NPs have been designed and explored as diagnostic and/or therapeutic drug delivery vehicles. To achieve selective treatment and to reduce toxicity, these nanoparticles are usually endowed with targeting abilities. Passive targeting is based on the extravasation and enhanced permeability and retention effect of tumors, while active targeting always involves binding to specific ligands that are recognizable by CRC tissues, such as vascular endothelial growth factor, folate, monoclonal antibodies (mAbs), aptamers, and membrane penetrating peptides. In addition, contrast agents, such as gadolinium complexes and iron oxide particles, can be introduced into the delivery system to enable MR imaging and lesion detection. Furthermore, smart carriers have been gradually applied to the delivery system. These carriers are designed to respond to certain changes in the bio-environment and release encapsulated contents on demand, thus achieving effective drug concentrations at tumor sites. This review focuses on recent advances of NP technology for the targeted diagnosis and treatment of CRC and aims to unveil the emerging possibilities of using nanocarriers to enhance therapeutic applications.
KW - Active control
KW - Colorectal cancer targeted
KW - Drug delivery
KW - MR imaging
UR - http://www.scopus.com/inward/record.url?scp=84978200022&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978200022&partnerID=8YFLogxK
U2 - 10.2174/1568009616666151130214442
DO - 10.2174/1568009616666151130214442
M3 - Review article
C2 - 26632434
AN - SCOPUS:84978200022
SN - 1568-0096
VL - 16
SP - 536
EP - 550
JO - Current cancer drug targets
JF - Current cancer drug targets
IS - 6
ER -